Belzutifan for Ocular Tumors in Patients with von Hippel-Lindau Disease
While early reports are encouraging, the optimal dose of the drug for controlling RH along with the duration of therapy, role as a neoadjuvant, and ways to incorporate use of the drug into the treatment and screening paradigms for VHL-associated ocular disease are evolving.
Authors
- Farzad Jamshidi (ORCID: https://orcid.org/0000-0001-7327-8044)
- Lola Lozano (ORCID: https://orcid.org/0000-0002-0492-4759)
- H. Culver Boldt (ORCID: https://orcid.org/0000-0002-7292-2093)
- Elaine M. Binkley (ORCID: https://orcid.org/0000-0003-0464-3372)
- S S Tadros
Institutions
- University of Iowa (US)
- University of Pittsburgh Medical Center (US)
Publication Details
- Journal
- Ocular Oncology and Pathology
- Published
- 2025-09-30
- DOI
- https://doi.org/10.1159/000548701
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00